Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.

1 August 2014. doid: 10.5414/CP202091

De Kam PJ, Kruithof AC, van Lierop MJ, Moerland M, Dennie J, Troyer MD, Langdon RB, Gutstein DE, Burggraaf J, El Galta R

View publication

To investigate the potential effect of sugammadex on anti-Xa anticoagulantactivity of enoxaparin and the activated partial thromboplastin time (APTT) of unfractionated heparin (UFH).

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact

Therapeutic Areas

challenges

methods

Trial Services

Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.

Advancing the boundaries of clinical drug development